16. The method according to claim 15 , further comprising: establishing a database of hierarchical safety and efficacy attributes, the attributes arranged in a parent-child relationship fashion in accordance with medical ontology; and symbolically representing each attribute as a data object.
17. The method according to claim 16 , wherein the attributes include drug, disease and allergy term definitions, the method further comprising: establishing interaction dimensions between and among the term definitions; and defining an interaction severity score for a particular drug based on the severity of a drug-drug interaction dimension.